

Insulin Resistance

Copyright By Pamela W. Smith, M.D., MPH, MS

Complete References

1. Nichols G, et al. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis. *Amer Jour Med.* 2008; 121(6):519-24.
2. Bjornholt J, et al. Fasting blood glucose: an underestimated risk factor for cardiovascular death. Results from a 22-year follow-up of healthy nondiabetic men. *Diabetes Care.* 1999; 22(1):45-9.
3. Batty G, et al. Post challenge blood glucose concentration and stroke mortality rates in non-diabetic men in London: 38-year follow-up of the original Whitehall prospective cohort study. *Diabetologia.* 2008; 51:1123-26.
4. Cherbuin N, et al. Higher normal fasting plasma glucose is associated with hippocampal atrophy: The PATH Study. *Neurology.* 2012; 79(10):1019-26.
5. Pelia R, et al. Fasting insulin and incident dementia: in an elderly population of Japanese-American men. *Neurology.* 2004; 63(2):228-33.
6. Schwarzbein D. *The Schwarzbein Principle II.* Health Communications, IN., Deerfield Beach, Florida, 2002.
7. Kligler B, et al. An integrative approach to the management of type 2 diabetes mellitus. *Altern Therapies.* 2003; 9(6):24-32.
8. Kelly G. Insulin Resistance: Lifestyle and Nutritional Interventions. *Altern Therapies.* 2000; 5(2)
9. Hu F, et al. Diet, lifestyle, and the risk of type 2 diabetes in women. *NEJM.* 2001; 345:790-97.
10. Tuomilehto J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *NEJM.* 2001; 344:1343-50.
11. Wolever T, et al. Beneficial effect of low-glycemic index diet in overweight NIDDM subjects. *Diabetes Care.* 1992; 15(4):562-64.
12. Wolever T, et al. The glycemic index. *World Rev Nutrition Dietetics.* 1990; 62:120-85.
13. Jenkins D, et al. Metabolic effects of a low-glycemic-index diet. *Amer Jour Clin Nutr.* 1987; 46(6):908-75.
14. The Sinatra Health Report, December 2003; p. 6.
15. Fung T, et al. Whole-grain intake and the risk of type 2 diabetes: a prospective study in men. *Amer Jour Clin Nutr.* 2002; 76:535-40.
16. Montonen J, et al. Whole-grain and fiber intake and the incidence of type 2 diabetes. *Amer Jour Clin Nutr.* 2003; 77:622-9.
17. Meyer K, et al. Carbohydrates, dietary fiber, and incident type 2 diabetes in older women. *Amer Jour Clin Nutr.* 2000; 71:921-30.



18. Salmeron J, et al. Dietary fiber, glycemic load, and risk of NIDDM. *Diabetes Care*. 1997; 20(4):545-5.
19. Meyer K, et al. Carbohydrates, dietary fiber, and incident type 2 diabetes in older women. *Amer Jour Clin Nutr*. 2000; 71:921-30.
20. Salmeron J, et al. Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. *JAMA*. 1997; 277:472-7.
21. Vitelli L, et al. Association of dietary composition with fasting serum insulin level: the ARIC study. *Nutr Metab Cardiovasc Dis*. 1996; 81:892-7.
22. Anderson J, et al. Fiber and health: an overview. *Amer Jour Gastroenterol*. 1986; 81:892-7.
23. Mertz W, et al. Interaction of chromium with insulin: a progress report. *Nutr Rev*. 1998; 56:174-77.
24. Anderson R, et al. Chromium, glucose intolerance, and diabetes. *Jour Amer Coll Nutr*. 1998; 17(6):548-55.
25. Estrada D, et al. Stimulation of glucose uptake by the natural coenzyme alpha lipoic acid/thioctic acid. *Diabetes*. 1996; 45:1798-1804.
26. Packer L, et al. Neuroprotection by the metabolic antioxidant alpha lipoic acid. *Free-radical Biol Med*. 1997; 22:359-78.
27. Kao W, et al. Serum and dietary magnesium and the risk of type 2 diabetes mellitus: The Atherosclerosis in Communities Study. *Arch Int Med*. 1999; 159(18):2151-59.
28. Rodriguez-Moran M, et al. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. *Diabetes Care*. 2003; 26(4):1147-52.
29. Lima M, et al. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. *Diabetes Care*. 1998; 21:682-86.
30. Goldfine A, et al. Vanadium improves insulin sensitivity. *Jour Clin Endocrin Metabol*. 1995; 80(11):3311-19.
31. Cohen N, et al. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. *Amer Society Clin Invest*. 1995; 95:2501-09.
32. Goldfine A, et al. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. *Metabolism*. 2000; 49(3):400-410.
33. Chiu K, et al. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. *Amer Jour Clin Nutr*. 2004; 79:820-25.
34. Borissova A, et al. The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. *Int Jour Clin Pract*. 2003; 57(4):258-61.
35. Luo J, et al. Dietary polyunsaturated (n-3) fatty acids improve adipocyte insulin action and glucose metabolism in insulin-resistant rats: relation to membrane fatty acids. *Jour Nutr*. 1996; 126:1951-58.
36. Houseknecht K, et al. Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty fa/fa rat. *Biochem Biophys Res Commun*. 1998; 247(3):911.
37. Lukaczer D. Nutritional support for insulin resistance. *App Nutr Sci Reports*. 2001; p.1-8.
38. Zhang H, et al. Biotin administration improves the impaired glucose tolerance of streptozotocin-induced diabetic Wistar rats. *Jour Nutr Sci Vitaminol*. 1997; 43:271-80.

39. Salonen J, et al. Increased risk of non-insulin dependent diabetes mellitus at low plasma vitamin E concentrations: a four year follow up study in men. *BMJ*. 1995; 311:1124-27.
40. Paolisso G, et al. Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin dependent diabetic patients. *Amer Jour Clin Nutr*. 1993; 57:650-56.
41. Paolisso G, et al. Pharmacological doses of vitamin E and insulin action in elderly subjects. *Amer Jour Clin Nutr*. 1994; 59:1291-96.
42. De Grandis D, et al. Acetyl-L-carnitine in the treatment of diabetic neuropathy: a long-term, randomized, placebo-controlled study. *Drugs R D*. 2002; 3(4):223-31.
43. Mingrone G, et al. L-carnitine improves glucose disposal in type 2 diabetic patients,” *Jour Amer Coll of Nutr*. 1999; 18:77-82.
44. Hipkiss A, et al. Carnosine, the anti-ageing, anti-oxidant dipeptide, may react with protein carbonyl groups. *Mech Ageing Dev*. 2001; 122:1431-45.
45. Kim K, et al. Taurine ameliorates hyperglycemia and dyslipidemia by reducing insulin resistance and leptin level in Otsuka Long-Evans Tokushima fatty (OLETF) rats with long-term diabetes. *Exp Mol Med*. 2012; 44(11):665-73.
46. Birdsall T, et al. Therapeutic applications of taurine. *Altern Med Rev*. 1998; 3:128-36.
47. Nakaya Y, et al. Taurine improves insulin sensitivity in the Otsuka Long-Evans Tokushima fatty rat, a model of spontaneous type 2 diabetes. *Amer Jour Clin Nutr*. 2000; 71:54-58.
48. Macleavy I. The forgotten longevity benefits of taurine. *Life Extension*. July 2013; p. 38-46.
49. Wascher T, et al. Effects of low-dose L-arginine on insulin-mediated vasodilation and insulin sensitivity. *Eur Jour Clin Invest*. 1997; 27:690-95.
50. Yeh, G, et al. Systematic review of herbs and dietary supplements for glycemic control in diabetes. *Diabetes Care*. 2003; 26(4):1277-94.
51. Nahas R. Type 2 Diabetes. In Rakel, D., *Integrative Medicine*. 3rd Ed. Philadelphia: Elsevier, 2012, p. 297-311.
52. Imanshahidi M, et al. Pharmacological and therapeutic effects of *Berberis vulgaris* and its active constituent, berberine. *Phytother Res*. 2008; 22:999-1012.
53. Vuskan V, et al. American ginseng (*Panax quinquefolius* L) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus. *Arch Intern Med*. 2000; 160(7):1009-13.
54. Vuskan V, et al. Konjac-Mannan and American ginseng emerging alternatives therapies for type 2 diabetes mellitus. *Jour Amer Coll Nutr*. 2001; 20(5 Supp):370S-380S; discussion 381S-383S.
55. Ibid., Nahas.
56. “Fenugreek.” *Alternative Medicine Review*. 2003; 8(1): 21-27.
57. Sharma R, et al. Effect of fenugreek seeds and leaves on blood glucose and serum insulin responses in human subjects. *Nutr Res*. 1986; 6:1353-64.
58. Madar Z, et al. Glucose-lowering effect of fenugreek in non-insulin dependent diabetics. *Eur Jour Clin Nutr*. 1988; 42:51-54.
59. Ali L, et al. Characterization of the hypoglycemic effects of *Trigonella foenum graecum* seed. *Planta Med*. 1995; 61:358-360.
60. Patil S, et al. Allergy to fenugreek (*Trigonella foenum graecum*). *Ann Allergy Asthma Immunol*. 1997; 78:297-300.

61. Sharma R. Effect of fenugreek seeds and leaves on blood glucose and serum insulin responses in human subjects. *Nutr Res.* 1986; 6:1353-64.
62. Sharma R, et al. Toxicological evaluation of fenugreek seeds: a long-term feeding experiment in diabetic patients. *Phytother Res.* 1996; 10:519-520.
63. Sharma R, et al. An evaluation of hypocholesterolemic factor of fenugreek seeds (*T foenum graecum*) in rats. *Nutr Rep Int.* 1986; 33:669-77.
64. Lambert J, et al. Potential interaction between warfarin and boldo-fenugreek. *Pharmacotherapy.* 2001; 21:509-512.
65. Abdel-Barry J, et al. Hypoglycaemic effect of aqueous extract of the leaves of *Trigonella foenum-graecum* in healthy volunteers. *East Mediterr Health Jour.* 2000; 6:83-88.
66. Panda S, et al. Inhibition of triiodothyronine production by fenugreek seed extract in mice and rats. *Pharmacol Res.* 1999; 40:405-09.
67. Srivastava Y, et al. Antidiabetic and adaptogenic properties of *Momordica charantia* extract: an experimental and clinical evaluation. *Phytotherapy Res.* 1993; 7:285-89.
68. Yeh G, et al. Systematic review of herbs and dietary supplements for glycemic control in diabetes. *Diabetes Care.* 2003; 26(4):1277-94.
69. Welihinda J, et al. Effect of *Momordica charantia* on the glucose tolerance in maturity onset diabetes. *Jour Ethnopharmacol.* 1986; 17:277-82.
70. Leatherdale B, et al. Improvement in glucose tolerance due to *Momordica charantia* (Karela). *BMJ.* 1981; 282:1823-24.
71. Yongchaiyudha S, et al. Antidiabetic activity of aloe vera L. juice: clinical trial in new cases of diabetes mellitus. *Phytomedicine.* 1996; 3:241-43.
72. Frati-Munari A, et al. Hypoglycemic effect of *Optunia streptacanthalenaire lemaire* in NIDDM. *Diabetes Care.* 1988; 11(1):63-66.
73. Frati A, et al. Influence of nopal intake upon fasting glycemia in type II diabetics and health subjects. *Arch Invest Med.* 1991; 22(1):51-56.
74. Baskaran K, et al. Antidiabetic effect of a leaf extract form *Gymnema sylvestre* in non-insulin-dependent diabetes mellitus patients. *Jour Ethnopharmacol.* 1990; 30:295-305.
75. Shanmugasundaram E, et al. Use of *Gymnema sylevestre* leaf extract in the control of blood glucose in insulin-dependent diabetes mellitus. *Jour Ethnopharmacol.* 1990; 30:281-94.
76. Ibid., Baskaran.
77. Khan A, et al. Insulin potentiating factor and chromium content of selected foods and spices. *Biol Trace Element Res.* 1990; 24:183-188.
78. Imparl-Radosevich J, et al. Regulation of PTP-1 and insulin receptor kinase by fractions from cinnamon: implications for cinnamon regulation of insulin signaling. *Horm Res.* 1998; 50:177-182.
79. Anderson R, et al. Tea enhances insulin activity. *Jour Agric Food Chem.* 2002; 50:7182-86.
80. Han M, et al. Epigallocatechin gallate, a constituent of green tea, suppresses cytokine-induced pancreatic B-cell damage. *Experimental and Molecular Med.* 2003; 35(2):136-39.
81. Wainstein J, et al. Olive leaf extract as a hypoglycemic agent in both human diabetic subjects and in rats. *Jour Med Food.* 2012; 15(7):605-10.
82. Gonzalez M, et al. Hypoglycemic activity of olive leaf. *Planta Med.* 1992; 38(6):513-15.
83. Everson J. Unexpected benefits of olive leaf extract. *Life Extension.* June 2013, p. 28-35.
84. Al-Azzawie H, et al. Hypoglycemic and antioxidant effect of oleuropein in alloxan-diabetic rabbits. *Life Sci.* 2006; 78(12):1371-77.

85. Jemai H, et al. Antidiabetic and antioxidant effects of hydroxytyrosol and oleuropein from olive leaves in alloxandiabetic rats. *Jour Agric Food Chem.* 2009; 57(19):8798-804.
86. Poudyal H, et al. Olive leaf extract attenuates cardiac, hepatic, and metabolic changes in high carbohydrate-high fat-fed rats. *Jour Nutr.* 2010; 140(5):946-53.
87. de Bock M, et al. Olive (*Olea europaea* L.) leaf polyphenols improve insulin sensitivity in middle-aged overweight men: a randomized, placebo-controlled, crossover trial. *PLoS One.* 2013; 8(3):e57622.
88. Nagendran M. Effect of green coffee bean extract (GCE), high in chlorogenic acids, on glucose metabolism. Poster presentation number: 45-LB-P. *Obesity.* 2011; the 29th Annual Scientific Meeting of the Obesity Society, Orlando Florida. October 1-5, 2011.
89. Zibadi S, et al. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by pycnogenol supplementation. *Nutr Res.* 2008; 28:315-20.
90. Ibid., Nahas.
91. Kahn A, et al. Treatment of diabetes with *Coccinia indica*. *BMJ.* 1980; 280:1044.
92. Kuriyan R, et al. Effect of supplementation of *Coccinia cordifolia* extract on newly detected diabetic patients. *Diabetes Care.* 2008; 31:216-20.
93. Mohan R, et al. Water-soluble polyphenol-rich clove extract lowers pre- and post-prandial blood glucose in healthy and prediabetic volunteers: an open label pilot study. *BMC Complement Altern Med.* 2019; 19(1):99.
94. Hidalgo J, et al. Delphinol (R) standardized maqui berry extract reduces postprandial blood glucose increase in individuals with impaired glucose regulation by novel mechanism of sodium glucose cotransporter inhibition. *Panminerva Med.* 2014; 56(2 Suppl 3):1-7.
95. Alvarado J, et al. Delphinol (R): standardized maqui berry extract significantly lowers blood glucose and improves blood lipid profile in prediabetic individuals in three-month clinical trial. *Panminerva Med.* 2016; 58(3 Suppl 1):1-6.
96. Mollace V, et al. Hypolipemic and hypoglycaemic activity of bergamot polyphenols: from animal models to human studies. *Fitoterapia.* 2011; 82(3):309-16.
97. Nauman M, et al. Clinical application of bergamot (*Citrus bergamia*) for reducing high cholesterol and cardiovascular disease markers. *Integ Food Nutr Metab.* 2019; 6(2):10. 15761/IFNM.1000249.
98. Giglio R, et al. The effect of bergamot on dyslipidemia. *Phytomedicine.* 2016; 23(11):1175-81.
99. Mannucci C, et al. Clinical pharmacology of citrus bergamia: A systematic review. *Phytother Res.* 2017; 31(1):27-39.
100. Perna S, et al. Efficacy of bergamot: From anti-inflammatory and anti-oxidative mechanisms to clinical applications as preventive agent for cardiovascular morbidity, skin diseases, and mood alterations. *Food Sci Nutr.* 2019; 7(2):369-84.

MycoPul™ Exceptionally pure, vigorous mycotoxin binder



Researched Nutritionals
solutions for life